PTGX Overview

Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).

Wall Street analysts forecast PTGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTGX is94.54 USD with a low forecast of 65.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Protagonist Therapeutics Inc revenue for the last quarter amounts to 56.37M USD, increased 99.03

Protagonist Therapeutics Inc. EPS for the last quarter amounts to 0.05 USD, decreased -126.32

Protagonist Therapeutics Inc (PTGX) has 132 emplpoyees as of June 01 2026.

Today PTGX has the market capitalization of 6.40B USD.